Abstract: The present invention provides a single unit composition for lactation improvement comprising herbal galactagogue and a method for using the same. In one particular embodiment, the single unit composition of the invention comprises fenugreek and a mixture of essential minerals and vitamins.
Abstract: The present invention discloses a blood lipid-reducing composition, the active components of the composition are composed of fish oil, linseed oil, phytosterol ester or phytosterol. The composition mainly comprises components such as a-linolenic acid, EPA, DHA and phytosterol or phytosterol ester, can reduce serum total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C), has an efficacy of reducing blood lipid. The present invention also discloses the use of the blood lipid-reducing composition in the manufacture of health food having a function of reducing blood lipid.
Abstract: The invention relates to a composition containing extracts of the fruit of Hoveniadulcis Thunb., gallocatechin, and methyl vanillate as active ingredients for preventing and treating bone disease. The extracts of the fruit of Hoveniadulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention are natural materials and thus cause no side effects, and may activate the Wnt/?-catenin pathway to promote bone formation rather than inhibiting bone decomposition, and therefore may be effective in treating osteoporosis and related diseases. In addition, the extracts of the fruit of Hoveniadulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention may have the effects regrowing hair and preventing and treating wounds and metabolic diseases related to the activation of Wnt/?-catenin pathway.
Abstract: A healthcare foodstuff having an anti-diabetic effect and effective for treating type 2 diabetes mellitus. The healthcare foodstuff comprises effective ingredients and adjuvant(s), including Paederia scandens, coicis semen, pork and citri reticulatae pericarpium. Also disclosed is method of manufacturing the healthcare foodstuff useful in the treatment of type 2 diabetes mellitus.
Abstract: Compositions and methods are presented that substantially increase levels of BDNF in blood, and even more pronouncedly exosomal BDNF levels. Suitable compositions include whole coffee fruit extracts and powders or procyanidin-enriched preparations that are orally administered at relatively low dosages. The augmentation of the levels of natural stimulating factor takes place in cerebral circulation.
Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, pharmaceutical compositions for effecting such prevention and interval treatment thereof.
Type:
Application
Filed:
June 20, 2013
Publication date:
February 11, 2016
Inventors:
Hermann RUSS, Wojciech DANYSZ, Christopher Graham Raphael FARSONS
Abstract: Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of Glyoxalase 1 (GLO1). In some embodiments, the inhibitor is a small molecule. In certain embodiments, the disease or disorder is a sleep disorder, a mood disorder such as depression, epilepsy, an anxiety disorder, substance abuse, substance dependence or substance such as an alcohol withdrawal syndrome.
Abstract: The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of Marfan Syndrome and/or a Marfan-related disorder is reduced in intensity, severity, duration, or frequency or has delayed in onset.
Abstract: Synuclein-gamma (SNCG) inhibitors are useful for inhibiting or treating angiogenesis, endometriosis and/or endometrial lesion growth. They also potentiate efficacy of other hormonal agents in treating angiogenesis, endometriosis and/or endometrial lesion growth.
Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 11, 2016
Applicant:
Cedars-Sinai Medical Center
Inventors:
Mark Pimentel, Ruchi Mathur, Christopher Chang
Abstract: The invention relates to at least one molecular target for healing or treating wounds and, in particular chronic, human wounds. The molecular target is nWASP or a protein at least 75% homologous therewith and which retains the same activity as nWASP protein, such as WASP. Further, the invention concerns a novel therapeutic for treating said wounds and a novel gene therapy approach, involving said molecular target, for treating said wounds.
Abstract: The present invention provides therapeutic and prophylactic compositions for use in treating and preventing disorders involved epithelial cell apoptosis, such as gastrointestinal disorders (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis) in a subject, such as a human patient.
Abstract: Compositions and methods for treating toxicity associated with exposure to radiation and side effects of treatments for hyperproliferative disorders are provided. Typically the compositions are administered in an effective amount reduce one or more adverse side effects. The side effects to be treated include, but are not limited to reduced appetite and weight loss. The methods typically include administering to a subject a composition including a protein transduction domain, a target signal, and a transcription factor A—mitochondrial polypeptide in an amount effective to inhibit, reduce or alleviate weight loss or to increase or induce appetite.
Abstract: The present disclosure provides compositions and methods useful for treating or preventing diseases or disorders where beta amyloid accumulation or aggregation contributes to the pathology or symptomology of the disease, for example Alzheimer's disease.
Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.
Type:
Application
Filed:
March 31, 2015
Publication date:
February 11, 2016
Inventors:
Christopher John BROWN, Cheng San Brian Chia
Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
Type:
Application
Filed:
August 7, 2015
Publication date:
February 11, 2016
Applicant:
Anchored RSK3 Inhibitors, LLC
Inventors:
Michael S. KAPILOFF, Jinliang Li, Michael Kritzer, Catherine Passariello, Kimberly Dodge-Kafka
Abstract: The present invention concerns particles containing at least one covalently cross-linked polysaccharide and at least one growth factor, a method of preparation, and uses thereof.
Type:
Application
Filed:
October 21, 2015
Publication date:
February 11, 2016
Applicants:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), UNIVERSITE DE ROUEN, UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE
Inventors:
Ebba BRAKENHIELM, Sébastien BANQUET, Florence EDWARDS-LEVY, Christian THUILLEZ
Abstract: Methods of predicting the immunogenicity of a therapeutic protein in a subject are provided and the use of this method in selecting a protein for replacement therapy having the fewest immunogenic epitopes. The method is demonstrated by reference to ADAMTS13. Isolated allelic variants of ADAMTS13 that contribute to the variability in risk for both arterial and venous thrombotic disease development are provided. The allelic variants are identified as single nucleotide polymorphisms (ns-SNPs) in the ADAMTS13 gene, which result in haplotypes identified as H1 to H14. A method for improving outcomes of transfusions/transplant products is also provided by selection of haplotype matched therapeutics.
Abstract: Therapeutic compositions for treatment of protein serine/threonine phosphatase-related diseases are obtained by engineering amino acid sequences that disrupt interaction between the protein serine/threonine phosphatase and a protein inhibitor and are provided herein. Calcineurin and PPI are examples of protein serine/threonine phosphatases. RCAN1 is an inhibitor of calcineurin and is overexpressed in patients with serious diseases, such as Down syndrome and Alzheimer's disease. Molecules that bind RCAN1 at regions that interact with calcineurin selectively modulate functions of calcineurin to treat these diseases. Methods of treating a subject for a protein serine/threonine phosphatase-related disease by administering a molecule having an amino acid sequence selected from the group of SEQ ID NOs: 1-19 are further provided.
Abstract: The present invention relates to methods of treating or preventing a bacterial disease or infection, antibacterial compositions, and antibacterial surfaces, including isolated endolysin polypeptides from bacteriophage GRCS.
Abstract: The invention relates to a combination preparation containing a selective cell death-inducing binary enzyme system for use in the therapy and/or treatment of cancer and tumors in humans and animals, a process, and its use.
Type:
Application
Filed:
January 17, 2014
Publication date:
February 11, 2016
Applicant:
SIT-Soft Intelligent Therapeutics GmbH & Co. KG
Abstract: The present invention relates to a therapeutic composition including a ceramidase mixture and a pharmaceutically acceptable carrier, where the ceramidase mixture includes an inactive acid ceramidase precursor and an active acid ceramidase. The invention also relates to a method of acid ceramidase treatment, including formulating the acid ceramidase used in said treatment as a ceramidase mixture, where the ceramidase mixture includes an inactive acid ceramidase precursor and an active acid ceramidase. The invention further relates to a method of producing a therapeutic composition including providing a medium containing an inactive acid ceramidase precursor; incubating the medium under conditions effective to transform a portion of the inactive acid ceramidase precursor to active acid ceramidase; and recovering the incubated medium as a ceramidase mixture comprising the inactive acid ceramidase precursor and an active acid ceramidase.
Abstract: This disclosure relates to tolerance inducing peptide (TIP) derived from the amino acid reference locus (AARL) within a FVIII replacement product (FVIIIrp) based on the differences between the expression product of a subject's F8 gene (sFVIII) and the FVIIIrp to provide tolerance induction before, during, and/or after a FVIII replacement therapy in a subject suffering from Hemophila A. Methods of deriving, making, and using the TIP are also disclosed. In some embodiments, the TIP is associated with a nanoparticle, e.g., PLGA or PLGA-PEMA nanoparticle.
Abstract: Provided herein are immunogenic compositions (vaccines) and methods for immunizing a subject with the immunogenic compositions for inducing an adaptive immune response directed specifically against senescent cells for treatment and prophylaxis of age-related diseases and disorders, and other diseases and disorders associated with or exacerbated by the presence of senescent cells. The immunogenic compositions provided herein comprise at least one or more senescent cell-associated antigens, polynucleotides encoding senescent cell-associated antigens, and recombinant expression vectors comprising the polynucleotides for use in administering to a subject in need thereof.
Type:
Application
Filed:
December 3, 2013
Publication date:
February 11, 2016
Inventors:
Alain Philippe Vasserot, Serge Lichtsteiner, Judith Campisi
Abstract: The present invention relates to a plasmid comprising a sequence encoding for a fragment of p185neu chosen in the group consisting of SEQ ID 1, 2, 3, 4, 5, 6 carried by applying a pulsating voltage having an intensity comprised in the range from 100 to 200 V, through a needle electrode for use in the preventive or therapeutic treatment of subjects at risk of developing p185neu-positive tumors, or of patients with p185neu-positive primary tumors, metastasis or relapses.
Abstract: Disclosed herein are isolated human monoclonal antibodies, and functional fragments thereof, that specifically bind HMW-MAA. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect HMW-MAA in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed.
Type:
Application
Filed:
October 20, 2015
Publication date:
February 11, 2016
Applicant:
University of Pittsburgh - Of the Commonwealth System of Higher Education
Abstract: Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (MSI). The vaccine contains an MSI-specific frameshift peptide (FSP) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said FSP. The vaccine of the present invention is particularly useful for the prevention/treatment of colorectal cancer, endometrial cancer, gastric cancer or small bowel cancer.
Type:
Application
Filed:
October 29, 2015
Publication date:
February 11, 2016
Inventors:
Matthias Kloor, Miriam Reuschenbach, Magnus von Knebel-Doeberitz
Abstract: The present invention provides novel nucleotide sequence and other constructs used for expression of novel recombinant P. falciparum circumsporozoite proteins in bacterial cells such as E. coli. Processes are provided for producing a soluble recombinant P. falciparum CSP from E. coli. Methods to produce a human-grade, highly immunogenic anti-malaria vaccine based on CSP are shown. The novel recombinant P. falciparum circumsporozoite protein by itself or in combination with other malaria antigens or adjuvants can form the basis of an effective malaria vaccine.
Abstract: Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD154 polypeptide or an HMGB1 polypeptide.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 11, 2016
Inventors:
Lisa Bielke, Sherryll Layton, Billy Hargis, Neil R. Pumford, Olivia B. Faulkner, Luc Berghman, Daad ABI-GHANEM
Abstract: A vaccine for the prevention of infections with Bordetella, comprising at least outer membrane vesicles (OMVs) of B. parapertussis, excipients and/or adjuvants. Bordetella may be, for example, B. pertussis or B. parapertussis. The vaccine can comprise adjuvants, for example, aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof. In another preferred embodiment, the vaccine for the prevention of infections with Bordetella comprises at least outer membrane vesicles (OMVs) of B. pertussis and the lipopolysaccharide of B. parapertussis, excipients and/or adjuvants. The vaccine can comprise between 3 to 20 ?g per dose of OMVs from B. pertussis and between the amount equivalent to 107 and 1010 bacteria per dose of lipopolysaccharide of B. parapertussis. The adjuvant can be aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof. The Tdap vaccine exhibits cross activity.
Type:
Application
Filed:
March 25, 2014
Publication date:
February 11, 2016
Inventors:
Daniela HOZBOR, Daniela BOTTERO, María Emelia GAILLARD, Eugenia ZURITA, Maximiliano OMAZABAL, Darío FLORES, Agustina ERREA, Griselda MORENO, Martin RUMBO, Erika BARTEL, Celina CASTUMA
Abstract: The present invention features polynucleotides encoding hemagglutinin (HA) polypeptide variants of a wild-type A/Anhui/1/2013 HA polypeptide, H7N9 influenza A viruses comprising such modified HA polynucleotides, methods of growing such viruses, and immunogenic compositions comprising such polynucleotides.
Abstract: Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin and/or influenza B hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza A serotypes and/or influenza B serotypes, or combinations thereof, using the vaccines that are provided.
Type:
Application
Filed:
March 12, 2014
Publication date:
February 11, 2016
Applicant:
The Trustees of the University of Pennsylvania
Inventors:
David B. Weiner, Jian Yan, Matthew Morrow
Abstract: The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions.
Type:
Application
Filed:
August 6, 2015
Publication date:
February 11, 2016
Applicant:
MEDIGEN BIOTECHNOLOGY CORP.
Inventors:
Young-Sun Lin, Jinyi Cheng, Ya-Lin Chiang, Ming-Cheng Chen, Kuei-Tai A. Lai, Chih Ya Yang
Abstract: The present invention relates to the use of a non-reducing carbohydrate or carbohydrate derivative and at least one agent which inhibits dimer formation in a freeze-dried composition comprising at least one peptide that contains a free cysteine residue, to provide a freeze-dried composition with improved long-term storage stability.
Abstract: Disclosed are methods of treating or modulating cachexia and/or increasing lean body mass and/or increasing lower extremity muscle size in a prostate cancer patient comprising administering a therapeutically effective amount of a myostatin antagonist. Further disclosed is the peptibody sequence of the myostatin antagonist, and the formulation of the peptibody.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 11, 2016
Inventors:
Ian Desmond Padhi, Huiquan Han, Christopher Michael Haqq, Isaac Ciechanover
Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.
Abstract: The present invention features compositions and methods for targeted delivery of a therapeutic or imaging agent to a site accessible through the nose or mouth that may be difficult to effectively and efficiently treat otherwise (e.g., the middle ear, sinuses, or lung). The therapeutic or imaging agent is deposited onto a magnetic nanoparticle that is drawn through a passage or tissue that leads away from the nose or mouth by a magnetic field applied over the targeted site (e.g., by magnets within the ear canal or surrounding the ear).
Abstract: A method and an system for vaccinating a mammalian subject. The method includes the steps of: arranging a source of electromagnetic radiation proximate to a target zone of skin of the mammalian subject; controlling the source of electromagnetic radiation to deliver a dose of electromagnetic radiation to the target zone determined to create one or more thermally-denatured zones in the target zone; and intradermally injecting a vaccine within the target zone to vaccinate the mammalian subject. The system for vaccinating a subject may include an electromagnetic radiation source configured to be arranged proximate to a target zone on an exterior of the subject; a user control configured to selectively cause the electromagnetic radiation source to deliver a dose of electromagnetic radiation toward the target zone to create one or more thermally-denatured zones in the target zone; and a vaccine-delivery system configured to deliver a vaccine to the target zone.
Abstract: The present disclosure provides compositions (e.g., extended release compositions) which exhibit a desirable pharmacokinetic profile of an active agent while providing reduced dissolution sample variability, e.g., in the form of reduced inter-capsule variability and/or a reduction in storage-time dependent change in mean release of the active agent from the composition. Related methods of making and administering the disclosed compositions are also provided.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 11, 2016
Inventors:
Su Il Yum, Wendy Chao, Huey-Ching Su, Roger Fu, Michael S. Zamloot, Karl Bratin, Ravi M. Shanker
Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
Type:
Application
Filed:
October 21, 2015
Publication date:
February 11, 2016
Inventors:
Yoshiro Niitsu, Junji Kato, Yasushi Sato
Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Type:
Application
Filed:
October 26, 2015
Publication date:
February 11, 2016
Inventors:
Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
Abstract: Disclosed herein are methods and compositions for involving a xanthine oxidase inhibitor that has enhanced solubility. The compositions described herein include a xanthine oxidase inhibitor combined with an organic base. The compositions can be used to treat a disease or medical condition that involves elevated uric acid levels.
Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.
Type:
Application
Filed:
March 11, 2014
Publication date:
February 11, 2016
Applicants:
DURECT CORPORATION, ZOGENIX, INC.
Inventors:
Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks Boyd, Christopher M. RUBINO
Abstract: The present invention relates to a carrier that is targeted at fucosylated molecule-producing cells, which comprises an effective amount of fucose for targeting said cells, to a composition comprising the carrier, and to a method for treating and diagnosing a disease related to fucosylated molecule-producing cells utilizing said carrier, etc. The carrier of the present invention enables to deliver a substance specifically to fucosylated molecule-producing cells.
Abstract: Disclosed are polymers that are poly(beta-amino ester)s (PBAEs) modified with at least one oligopeptide. The polymers may be used in any field where polymers have been found useful including in medical fields, particularly in drug delivery. The polymers are particularly useful in delivering a polynucleotide such as DNA, RNA and siRNA, a small molecule or a protein. Also disclosed are compositions comprising said polymers and an active agent, methods of encapsulating an agent in a matrix of said polymers, and said polymers and compositions for use in medicine.
Type:
Application
Filed:
March 10, 2014
Publication date:
February 11, 2016
Inventors:
Salvador BORRÓS GÓMEZ, Victor RAMOS PÉREZ, Nathaly SEGOVIA RAMOS, Pere DOSTA PONS
Abstract: The present invention provides compositions, and related kits and methods, for formation of hydrogels. The compositions comprise one or more chemically crosslinkable agents dissolved in an aqueous solution to form a precursor solution. The chemically crosslinkable agents useful in the present invention are selected from polymers modified with a molecule selected from acrylate, maleimide, vinylsulfone, N-hydroxysuccinimide, aldehyde, ketone, carbodiimide, carbonate, iodoacetyl, mercaptonicotinamide, quinone, thiol, amine, and combinations thereof. The precursor solution is characterized as being in an aqueous form at a non-physiologic physical-chemical condition and undergoing gelation when in contact with another fluid or body at a physiologic physical-chemical condition.
Type:
Application
Filed:
April 17, 2014
Publication date:
February 11, 2016
Applicant:
Hong Kong University of Science and Technology
Abstract: The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.
Type:
Application
Filed:
January 13, 2015
Publication date:
February 11, 2016
Inventors:
Thomas Chen, Daniel Levin, Satish Pupalli
Abstract: The present disclosure provides conjugate structures and compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
Type:
Application
Filed:
May 5, 2015
Publication date:
February 11, 2016
Inventors:
Romas Alvydas Kudirka, Aaron Edward Albers, David Rabuka